PARIS, Nov. 6, 2013 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces, following the press release from November 4 th, that the acceleration of the clinical development program in ALS is in line with proof of efficacy experiments conducted in two different models that generated positive results of increased survival.
Two different animal experiments were conducted by Dr. Luis Barbeito from the Institut Pasteur de Montevideo (Uruguay) and by Dr. Patricia Cassina from the Facultad de Medicina, Universidad de la República, Montevideo.
One experiment was aimed at evaluation the effect of masitinib in mice models of ALS (SOD1G93A female mice). Treatment started at 90 days-old animals before symptoms onset and continued until complete paralysis. Assessments were performed at 12 weeks (baseline) and weekly until end stage of paralysis (18-20 weeks). Administration of masitinib significantly delayed age of symptoms onset, improved grip strength and weight loss compared to control animals.Other experiment was aimed at evaluating the effect of masitinib in a transgenic rat model of ALS (SOD1G93A rats). These rats develop a motor syndrome with symptoms and pathological features of the human disease. Animals were observed weekly for onset of disease symptoms, as well as disease progression to death during 12 weeks of treatment. Compared to control, masitinib prolonged the survival of ALS rats, delaying the progression of paralytic symptoms and weight loss, suggesting a protective effect of masitinib in motor neuron diseases. Dr Luis Barbeito explained "Because masitinib can modulate inflammation, there is a scientific rationale to evaluate masitinib in the treatment of ALS. The results from the preclinical experiments are encouraging considering that there is no treatment available to ALS other than riluzole which delays death only few months in humans. Preliminary data indicate that masitinib target glial cells that promote ALS progression. Thus, the positive results showed in the mouse and rat trials raise the possibility that masitinib might offer therapeutic benefits in ALS patients, slowing disease progression".
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV